Core Insights - Shandong Wohua Pharmaceutical reported a revenue of 817 million yuan for the fiscal year 2025, marking a year-on-year increase of 6.96% [1] - The net profit attributable to shareholders reached 95.71 million yuan, a significant increase of 162.93%, the highest growth rate in nearly a decade [1] Financial Performance - The company's operating cash flow increased by 25% year-on-year, indicating strong cash generation capabilities [2] - The asset-liability structure remains robust, with zero interest-bearing debt [1] Strategic Initiatives - Wohua Pharmaceutical plans to implement a cash dividend scheme of 1.46 yuan per 10 shares, building on a previous dividend of 1.20 yuan [2] - The company announced a strategic optimization and restructuring of its production system to achieve cost reduction through resource synergy and intelligent upgrades [2] Future Outlook - For 2026, the company aims to deepen its focus on traditional Chinese medicine, respond effectively to ongoing procurement policies, and expand its outpatient market [2] - Wohua Pharmaceutical will enhance its research and access strategies, aiming for operational efficiency through meticulous management practices [2]